汇宇制药: 股东减持股份计划时间届满暨减持股份结果公告

Summary of Key Points Core Viewpoint - The shareholder Shanghai Shuangsa Enterprise Management Consulting (Limited Partnership) did not execute its planned share reduction of 12,695,629 shares, which represents 2.997% of the total shares of Sichuan Huiyu Pharmaceutical Co., Ltd. during the designated period [1][2]. Group 1: Shareholder Holding Information - As of the announcement date, Shanghai Shuangsa holds 12,695,629 shares, accounting for 2.997% of the total share capital of the company [1]. - The shares held by Shanghai Shuangsa were acquired prior to the company's initial public offering (IPO) and have been tradable since October 26, 2022 [1]. Group 2: Reduction Plan Implementation Results - The reduction plan was initially disclosed on May 12, 2025, with a planned reduction period from June 3, 2025, to August 31, 2025 [2]. - During the reduction period, Shanghai Shuangsa did not sell any shares, resulting in a total reduction of 0 shares and a reduction percentage of 0% [2]. - The current holding remains at 12,695,629 shares, maintaining the same ownership percentage of 2.997% [2][3]. Group 3: Additional Details on Reduction Plan - The reduction plan did not specify a minimum reduction quantity or percentage [3]. - The plan was not terminated early and was consistent with the previously disclosed intentions [3].